GIMDx announces accelerated commercialization of IncellDx, Inc.’s (“IncellDx”) HPV E6/E7 OncoTect mRNA in situ Hybridization Detection Kit at its sister subsidiary, Improve Labs. The acceleration is facilitated by the recent publication of China continuation patent #201711037694.6., “Methods and Systems for Predicting Whether a Subject has a Cervical Intraepithelial Neoplasia Lesion from a Suspension Sample of Cervical Cells” and the previously issued IncellDx China patent #201180061996.1 of the same title.
Improve Labs in Guangzhou, China, is a specialty cancer diagnostics laboratory officially licensed by the Chinese government (similar to a US CLIA laboratory) and is actively working with Tier 3 hospitals in Guangdong Province and greater China. The publication of this patent is expected to decrease the time required for the test to receive regulatory approval in China.
Dr. Larry Liu, President and CEO of GIMDx states, ” to serve the rapidly growing Chinese cancer diagnostics market, Improve Medical will continue to introduce US sourced, innovative and advanced molecular diagnostic tests like IncellDx’s HPV OncoTect based on the application of next generation flow cytometry platforms.”
Dr. Bruce Patterson, CEO and founder of IncellDx said, “we are excited about these key additions to our extensive IP portfolio especially in the HPV/cervical cancer space. We are even more excited that these patents will accelerate Improve Medical’s commercial efforts for our collaboration in the Chinese IVD markets.”
